September 20, 2026 · Gynecologic oncology reports · DOI: 10.1016/j.gore.2026.102210

Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report

Listen to this summary

The authors investigate the efficacy of combining temozolomide and olaparib in treating a patient with ARID1A-mutated uterine carcinosarcoma, a scenario that has not been previously reported in clinical practice. The case study demonstrates a complete radiographic response after four cycles of this regimen, suggesting potential benefits for biomarker-selected patients with this cancer type. The findings support further prospective studies to evaluate this treatment combination in genomically characterized gynecologic cancers.

Chrissy Liu, Yasmin Abozenah, Thomas J Rutherford, Vaagn Andikyan, Adrian Kohut, Matthew L Anderson

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play